Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Capital expenditures
Kiniksa Pharmaceuticals International (KNSA) capital expenditures by quarter
Kiniksa Pharmaceuticals International's capital expenditures were $180K in Q3 2026 (third quarter 2026), -73% from Q2 2026. Over the last 7 quarters it ranged from $99K (Q1 2025) to $671K (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $180K | -73% | -73% |
| Q2 2026 | $663K | +312% | +302% |
| Q1 2026 | $161K | -75% | +63% |
| Q4 2025 | $633K | -6% | — |
| Q3 2025 | $671K | +307% | — |
| Q2 2025 | $165K | +67% | — |
| Q1 2025 | $99K | — | — |
Q3 2026 at a glance
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kiniksa Pharmaceuticals International's capital expenditures?
Kiniksa Pharmaceuticals International's capital expenditures were $180K in Q3 2026 (third quarter 2026), -73% from Q2 2026.
How has Kiniksa Pharmaceuticals International's capital expenditures changed?
Over the last 7 quarters it ranged from $99K (Q1 2025) to $671K (Q3 2025).
Q3 2026 results → · How Kiniksa Pharmaceuticals International makes money →